Cytek Biosciences, Inc. (CTKB)
4.675
+0.06
(+1.19%)
USD |
NASDAQ |
Sep 09, 13:52
Cytek Biosciences Debt to Equity Ratio : 0.1093 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.1093 |
| March 31, 2026 | 0.1109 |
| December 31, 2025 | 0.0966 |
| September 30, 2025 | 0.0929 |
| June 30, 2025 | 0.0904 |
| March 31, 2025 | 0.0696 |
| December 31, 2024 | 0.0701 |
| September 30, 2024 | 0.0884 |
| June 30, 2024 | 0.0853 |
| March 31, 2024 | 0.0432 |
| December 31, 2023 | 0.0844 |
| September 30, 2023 | 0.0431 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.0427 |
| March 31, 2023 | 0.0408 |
| December 31, 2022 | 0.0843 |
| September 30, 2022 | 0.0793 |
| June 30, 2022 | 0.0361 |
| March 31, 2022 | 0.0366 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.0155 |
| December 31, 2020 | 0.0155 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Agilent Technologies, Inc. | 0.5363 |
| Bio-Rad Laboratories, Inc. | 0.191 |
| Bruker Corp. | 0.7663 |
| Danaher Corp. | 0.5298 |
| Harvard Bioscience, Inc. | 5.959 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 446.93M |
| Total Liabilities (Quarterly) | 124.98M |
| Shareholders Equity (Quarterly) | 321.95M |
| Current Ratio | 4.481 |
| Net Debt Paydown Yield | -0.30% |